key: cord-0721019-hert77y1
authors: Li, Na; Zhao, Lingfeng; Zhan, Xianquan
title: Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
date: 2020-09-22
journal: J Cell Physiol
DOI: 10.1002/jcp.30055
sha: c6904a8c37099031b4e660a95fa2ab0cbad06546
doc_id: 721019
cord_uid: hert77y1

Viruses such as human cytomegalovirus (HCMV), human papillomavirus (HPV), Epstein–Barr virus (EBV), human immunodeficiency virus (HIV), and coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) represent a great burden to human health worldwide. FDA‐approved anti‐parasite drug ivermectin is also an antibacterial, antiviral, and anticancer agent, which offers more potentiality to improve global public health, and it can effectively inhibit the replication of SARS‐CoV‐2 in vitro. This study sought to identify ivermectin‐related virus infection pathway alterations in human ovarian cancer cells. Stable isotope labeling by amino acids in cell culture (SILAC) quantitative proteomics was used to analyze human ovarian cancer cells TOV‐21G treated with and without ivermectin (20 μmol/L) for 24 h, which identified 4447 ivermectin‐related proteins in ovarian cancer cells. Pathway network analysis revealed four statistically significant antiviral pathways, including HCMV, HPV, EBV, and HIV1 infection pathways. Interestingly, compared with the reported 284 SARS‐CoV‐2/COVID‐19‐related genes from GencLip3, we identified 52 SARS‐CoV‐2/COVID‐19‐related protein alterations when treated with and without ivermectin. Protein–protein network (PPI) was constructed based on the interactions between 284 SARS‐CoV‐2/COVID‐19‐related genes and between 52 SARS‐CoV‐2/COVID‐19‐related proteins regulated by ivermectin. Molecular complex detection analysis of PPI network identified three hub modules, including cytokines and growth factor family, MAP kinase and G‐protein family, and HLA class proteins. Gene Ontology analysis revealed 10 statistically significant cellular components, 13 molecular functions, and 11 biological processes. These findings demonstrate the broad‐spectrum antiviral property of ivermectin benefiting for COVID‐19 treatment in the context of predictive, preventive, and personalized medicine in virus‐related diseases.

example, the HCMV prevented NK cell activity by virus UL16 and UL142 proteins. HCMV has acquired a viral homolog of IL-10 to suppress anti-cytomegalovirus immunity (Holder & Grant, 2019) .

HCMV also downregulated the expression of major histocompatibility complex to prevent the antigen processing and presentation by virus US11, US2, and US3 proteins (Britt, 2008) . HCMV has also evolved proteins (UL36 and UL37) to prevent apoptosis of infected cells, which promoted HCMV dissemination within the host (Andoniou & Degli-Esposti, 2006) . EBV was a member of the herpesvirus family that could cause mononucleosis. Though lots of people were asymptomatic infections, but potential links between EBV and other lymphoproliferative diseases (nonmalignant, premalignant, and malignant diseases) were widely studied (Rezk, Zhao, & Weiss, 2018) , such as Burkitt lymphoma, Hodgkin's lymphoma, hemophagocytic lymphohistiocytosis, gastric cancer, central nervous system lymphomas, acute cerebellar ataxia (Nussinovitch, Prais, Volovitz, Shapiro, & Amir, 2003) , nasopharyngeal carcinoma, and hairy leukoplakia (Marques-Piubelli et al., 2020) . EBV can infect different kinds of cells, but viral tropism is preferred to B cells and epithelial cells. B cell membrane fusion was mediated by the threepart glycoprotein complexes of gHgL gp42; although epithelial cell membrane fusion was mediated by the two-part complexes of gHgL (Shannon-Lowe, Rowe, 2014) . About 90% of HPV were asymptomatic infections, but HPV infection would lead to either warts or precancerous lesions. The infected sites by HPV, especially the subtype HPV16 and HPV18, showed high risk of cancer, including cervix, vagina, vulva, mouth, penis, throat, and anus (Athanasiou et al., 2020) . HPV was believed to cause cancers in nonintegrated episomes and integrating into DNA. Some of the HPV genes (E6 and E7), acted as oncogenes to promote malignant transformation (Hoppe-Seyler, Bossler, Braun, Herrmann, & Hoppe-Seyler, 2018) . E6 protein bound to p53 protein and resulted in the inactivation of p53 (Almeida, Queiroz, Sousa, & Sousa, 2019) . E7 acted as the transforming protein and competed between retinoblastoma protein (pRb) for binding to transcription factor E2F, which pushed the cell cycle forward (Almeida et al., 2019) . SARS-CoV-2 lead to the outbreak of coronavirus disease 2019 and rapidly grew into a global pandemic. Scientists set out to develop a treatment for COVID-19, but no anti-SARS-CoV-2 drug or vaccine has been approved to solve the serious challenge (H. . In the whole world, more than 7 million people have infected SARS-CoV-2, including more than 400,000 deaths at the national level (Lai, Shih, Ko, Tang, & Hsueh, 2020) . Further studies to develop the safest and most effective ways to combat viral infections were urgent. Ivermectin has been demonstrated to limit infection by a number of viruses with potential broad-spectrum activity (Yang et al., 2020) . For example, ivermectin has been reported anti-HIV-1 reliant on importin α/β nuclear import (Wagstaff, Sivakumaran, Heaton, Harrich, & Jans, 2012) . Ivermectin could reduce MAPK pathway activation through the inhibition of PAK-1 activity. The high content screening also identified ivermectin as a promising drug against EBV-positive and EBV-negative nasopharyngeal carcinoma cells (Gallardo, Mariamé, Gence, & Tilkin-Mariamé, 2018) . Herpes genitalis and infections, which are caused by HPV in males, might have an effective treatment choice for oral ivermectin, but it has not been officially approved until now (Buechner, 2002) . More importantly, ivermectin was reported as an inhibitor of the SARS-CoV-2, which was able to produce an effect~5000-fold reduction in viral RNA with a single addition to cells infected with SARS-CoV-2 (Caly, Druce, Catton, Jans, & Wagstaff, 2020) .

Viruses remain one of the least well-understood pathogens. The lack of knowledge about mechanisms and host-parasite interactions limited success in developing vaccines. It is facing challenges on several fronts, including limitations in availability, high cost of production, high mutation probability, and high prevalence of resistance. Ivermectin, as an antiparasitic, anticancer, antibacterial, and antiviral agent, provided more potentiality to improve global public health. The present study used stable isotope labeling by amino acids in cell culture (SILAC) quantitative proteomics analysis to reveal ivermectinrelated proteomics profiling and molecular network alterations. We focused our attention on the virus-related pathways, such as HCMV infection, HPV infection, EBV infection, and HIV1 infection. More interestingly, a large number of identified proteins were reported to be related to SARS-CoV-2/COVID-19. These results indicated that ivermectin might be a broad-spectrum antiviral drug. SILAC quantitative proteomics proved the molecular mechanisms of ivermectin in virusrelated pathways. Furthermore, protein-protein interaction (PPI)based hub modules for SARS-CoV-2-related proteins discovered a key molecule in COVID-19 disease in the context of predictive, preventive, and personalized medicine (PPPM) in COVID-19. and maintained with 5% CO 2 and 37°C and medium renewal every 2 days. A total of 10 passages were treated with SILAC reagents with 12 C 14 N (light = L) and 13 C 15 N (heavy = H)-labeled amino acids to ensure complete incorporation of stable isotope into the cultured cells.

Our previous study found that when TOV-21G cells were treated with ivermectin (0-60 μM) for 24 h, the IC 50 was 22.54 μM for ivermectin, and also 20 μM ivermectin (it was less than IC 50 22.54 μM) significantly suppressed cell proliferation and migration of TOV-21G, and maintained TOV-21G cells in good shape (N. Li & Zhan, 2020) . Thus, TOV-21G cells cultured in the H-and L-stable isotope-labeled media were treated with 20 μM ivermectin in dimethyl sulfoxide (DMSO) or with the same amount of the DMSO as control, for 24 h. Ivermectin-treated TOV-21G cells were centrifuged (800g), washed with PBS (×3), and then suspended (30 min, 4°C) in protein isolation buffer [7 M urea, 2 mM thiourea, 4% CHAPS (3-[(3cholamidopropyl)-dimethylammonio]-1-propane), 100 mM dithiothreitol (DTT), and 2% ampholyte] with a vortex (×5). The extracted protein solution was centrifuged (13,000g, 20 min, 4°C). The supernatants were the extracted protein samples whose protein concentrations were examined with 2-D quant kit.

The extracted protein samples were ultrasonicated and centrifuged (14,000g, 25°C, 40 min). The H-and L-stable isotope-labeled proteins were equally mixed (1:1), separated with 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; 20 μg/lane; constant current 14 mA, 90 min), and stained with Coomassie brilliant blue. SDS-PAGE-separated proteins were subjected to reduction, alkylation, digestion with trypsin, and identification with mass spectrometry (MS). The efficiency of SILAC-isotope incorporation into proteins was estimated with Rappsilber's method (Rappsilber, Ishihama, & Mann, 2003) . For this study, the SILAC labeling efficiency was up to 97%. 

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed with clusterProfiler (https://bioconductor.org/ packages/release/bioc/html/clusterProfiler.html; Yu, Wang, Han, & He, 2012) to find the signaling pathway based on the identified protein (p < .05, and adjusted p < .05). The reported SARS-CoV-2related genes were searched by GenCLiP3 (http://ci.smu.edu.cn/ genclip3/; Wang et al., 2019) . Cytoscape ClueGO (Bindea et al., 2009 ) was used to reveal the biological processes (BPs), molecular functions (MFs), and cellular components (CCs) enriched from identified proteins (two-sided hypergeometric test, adjusted p < .05 corrected with Benjamini-Hochberg). The reported SARS-CoV-2-related genes were analyzed by STRING 10.0 (http://string-db.org/cgi/input. pl; Szklarczyk et al., 2015) with the confidence of parameter (coexpression score > 0.700) for PPI network construction. Then, the entire PPIs were analyzed with the molecular complex detection (MCODE; Bader & Hogue, 2003) using Cytoscape software (version 3.2.1; National Resource for Network Biology) to obtain hub modules (score > 6). The statistical significance was set as p < .05. A Benjamini-Hochberg was used to adjust p value for the probability of the association between the proteins in the pathway. (Table S1 ). Further KEGG pathway analysis revealed four virus-related pathways (Table 1) 

The reported SARS-CoV-2-related genes were searched by Gen-CLiP3, and 284 SARS-CoV-2-related genes were summarized (Table S2) . Furthermore, 52 SARS-CoV-2-related proteins were regulated by ivermectin (Table 2) The protein-protein interacted molecules with a coexpression score more than 0.7 were selected to construct PPI network of 284 SARS-CoV-2-related genes ( Figure 1a and Table S3 ). The entire PPI network was further analyzed using MCODE, which found three modules (module 1 score = 18, module 2 score = 11, and module 3 score = 7; Figure 1b Only gene sets with adjusted p value < .05 corrected with the Benjamini-Hochberg procedure were considered significant. The less p value and more significant enrichment were shown with the greater node size. The same color indicated the same function group. Among the groups, we chose a representative of the most significant term and lag highlighted. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 including HLA-A in chromosome 6, AKT1 in chromosome 14, and NFKB1 and CASP3 in chromosome 4 ( Figure 3b and Table S6 ).

Ivermectin, as an antiparasitic drug for a long time, was proved very safe in highly developed animals because the major mechanism was targeting the chloride-dependent channels of both glutamate and γ-aminobutyric acid that interrupts neurotransmission in invertebrates (lower developed animals). In human, a blood-brain barrier exists, which can well protect the central nervous system (Develoux, 2004) . Ivermectin rarely provoked drug resistance, and most of the side effects were related to the release of antigen, not ivermectin itself (Boussinesq, 2005) . The good tolerance of ivermectin was even shown in children or infants. A total of 170 infants and children (weight < 15 kg) were treated with oral ivermectin, and only seven subjects were reported mild adverse events but not very serious (Levy et al., 2020) . When evaluated the existing evidence for serious events (stillbirths, spontaneous abortions, neonatal death, and congenital anomalies) after ivermectin exposure in pregnant women, 893 women with pregnancy did not report low birth weight, neonatal deaths, preterm births, or maternal morbidity, which indicated that high safety of ivermectin, but it was still insufficient evidence to conclude the certain safety of ivermectin during pregnancy (Nicolas et al., 2020) . The study of pharmacokinetics for the antiparasitic drug ivermectin provided some reference values, which would be helpful for ivermectin used in other diseases. Subjects (n = 68) were treated with higher or more frequent doses than currently approved for human use (the highest FDA-approved ivermectin dose of 200 μg/kg). The results showed that ivermectin was generally well-tolerated even at 10 times the highest FDA-approved dose (2000 μg/kg), and rarely appeared associated with CNS toxicity.

Additionally, the mean area under the curve ratios were 1.24 and 1.40 for the 30 and 60 mg doses, respectively, which indicated that the accumulation of ivermectin was minimal (Guzzo et al., 2002) . The great number of patients treated with ivermectin showed that it was a safe and well-tolerated drug. It made ivermectin more likely to turn to great value in clinical application.

Ivermectin appeared to be a basis for the future development of antiviral agents, and many studies have been reported as a broad antiviral activity of ivermectin. For example, ivermectin caused the reduced synthesis of Chikungunya virus RNA, as well as downregulation of viral protein expression, to affect viral infectious cycle (Varghese et al., 2016) . Ivermectin has nuclear transport inhibitory properties and was proved to be a broad-spectrum inhibitor of importin α/β nuclear import through a high-throughput screen. Further, ivermectin was able to inhibit the replication of HIV-1 and dengue virus (Wagstaff et al., 2012) . One study also demonstrated that ivermectin treatment inhibits pseudorabies virus infection by disrupting viral DNA synthesis and progeny virus production in a dosedependent manner. In this process, the nuclear localization of UL42 was also affected by ivermectin via targeting the nuclear localization signal pathways (Lv et al., 2018) . In the present study, KEGG For example, ivermectin-induced autophagy was associated with decreased P21-activated kinase 1 (PAK1) expression via the ubiquitination-mediated degradation pathway (Dou et al., 2016) .

Due to the outbreak and pandemic of SARS-CoV-2, the whole world is concerned about this public health emergency. Epidemiological studies showed that SARS-CoV-2 had a quick transmission, and it estimated that each infection might result in 1.4 to 3.9 new infections when no preventive measures are taken (Benvenuto et al., 2020) . The virus primarily spreads through close contact or respiratory droplets. Many researchers proved that SARS-CoV-2 could bind to the receptor angiotensin-converting enzyme 2 (ACE2) to enter human cells (Letko, Marzi, & Munster, 2020) . Ivermectin, an FDA-approved antiparasitic drug, was reported many times in recent studies as an inhibitor of the SARS-CoV-2 (Caly et al., 2020) . Ivermectin mediated viral import by inhibiting the importin (IMPα/β1) and creating the acidic environment (Caly et al., 2020) . Caly et al.

reported a 5000-fold reduction between the ivermectin treatment group (5 μM ivermectin) and the control group in SARS-CoV-2 RNA levels. The IC 50 of ivermectin for the SARS-CoV-2 was calculated at approximately 2.5 μM. According to previous pharmacokinetic studies in healthy volunteers, it suggested that single doses up to 120 mg of ivermectin proved to be safe and well-tolerated (Chaccour, Hammann, Ramón-García, & Rabinovich, 2020) . In recent study, quantitative translatomics and SILAC-based proteomics identified the signaling pathway profile of the cellular responses to SARS-CoV-2 infection in human colon epithelial carcinoma cell line, including glycolysis, translation, splicing, proteostasis, and nucleotide synthesis (Bojkova et al., 2020) . In this study, SILAC was used to analyze the human ovarian cancer cell line TOV-21G. After 10 passages, TOV-21G cells were treated by 20 μmol/L ivermectin for 24 h.

Interestingly, compared with reported SARS-CoV-2/COVID-19related genes from GencLip3 (n = 284), we identified 52 SARS-CoV-2/COVID-19-related protein alterations when treated with and without ivermectin. For example, CD147 (BSG)-encoded protein was also a member of the immunoglobulin superfamily, and the reported possible direct viral invasion of progenitor/stem cells was via CD147 (BSG; Ulrich & Pillat, 2020) . RB1 was a negative regulator of the cell cycle and was the first tumor suppressor gene found. Structural homology with SARS-CoV-1 indicated that SARS-CoV-2 might directly impair pRb. Considering preeminent inflammatory response and strong oxidative stress by SARS-CoV-2, whether SARS-CoV-2 would be associated with high carcinogenic risk should be watched for long periods (Alpalhão, Ferreira, & Filipe, 2020) . Expression of elevated levels of pro-inflammatory cytokines was closely related to the acute lung injury and pathogenesis in SARS-CoV-infected patients, including IL-1β, MCP-1, IL-6, TNF-α, and TGF-β1 (He et al., 2006) . Our data also identified that ivermectin-regulated key interleukins in SARS-CoV-2-induced cytokine storm, such as TNFB1, IL18, and IL1F10. Ivermectin seemed to potentially act against novel coronavirus infection. We provided mechanisms of ivermectin used in the treatment of SARS-CoV-2 infection.

This study, to best of our knowledge, was the first to provide ivermectin-regulated virus-related pathways by SILAC quantitative proteomics analysis, which revealed a broad-spectrum antiviral property of ivermectin. More exciting thing was that the identified ivermectin-regulated proteins included some reported SARS-CoV-2- 

Insights into the impact of Ivermectin on some protein aspects linked to Culex pipiens digestion and immunity

Cervical cancer and HPV infection: Ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins

Persistent SARS-CoV-2 infection and the risk for cancer

Insights into the mechanisms of CMV-mediated interference with cellular apoptosis

Ivermectin: From theory to clinical application

HPV vaccination and cancer prevention

An automated method for finding molecular complexes in large protein interaction networks

ClueGO: A cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks

The 2019-new coronavirus epidemic: Evidence for virus evolution

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Manifestations of human cytomegalovirus infection: Proposed mechanisms of acute and chronic disease

Common skin disorders of the penis

Avermectins, new family of potent anthelmintic agents: Producing organism and fermentation

Primary human cytomegalovirus (HCMV) infection in pregnancy

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Ivermectin, a new broad-spectrum antiparasitic agent

Ivermectin and COVID-19: Keeping rigor in times of urgency

Ivermectin: Enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations

Macrophage P2X4 receptors augment bacterial killing and protect against sepsis

Suppressing ROS-TFE3-dependent autophagy enhances ivermectin-induced apoptosis in human melanoma cells

Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling

Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer

Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth. Drug Design

Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects

Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS

Human cytomegalovirus IL-10 augments NK cell cytotoxicity

The HPV E6/E7 Oncogenes: Key factors for viral carcinogenesis and therapeutic targets

HIV prevention

Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway

The multitargeted drug ivermectin: From an antiparasitic agent to a repositioned cancer drug

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Ivermectin-Old drug, new tricks?

Ivermectin induces apoptosis of porcine trophectoderm and uterine luminal epithelial cells through loss of mitochondrial membrane potential, mitochondrial calcium ion overload, and reactive oxygen species generation

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Ivermectin safety in infants and children under 15 kg treated for scabies: A multicentric observational study

Updated Approaches against SARS-CoV-2

Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes

Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo

Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: A review

How to evolve the response to the global HIV epidemic with new metrics and targets based on pretreatment CD4 counts

Safety of oral ivermectin during pregnancy: A systematic review and meta-analysis

Post-infectious acute cerebellar ataxia in children

Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment

Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics

RIG-I-like receptors: Their regulation and roles in RNA sensing

Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update

Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea

Epstein Barr virus entry; kissing and conjugation. Current Opinion in Virology

STRING v10: Protein-protein interaction networks, integrated over the tree of life

CD147 as a target for COVID-19 treatment: Suggested effects of azithromycin and stem cell engagement

Resistance of field strains of Haemonchus contortus to ivermectin, closantel, rafoxanide and the benzimidazoles in South Africa

Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

GenCLiP 3: Mining human genes' functions and regulatory networks from PubMed based on co-occurrences and natural language processing

Grouper PKR activation inhibits red-spotted grouper nervous necrosis virus (RGNNV) replication in infected cells

The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer

ClusterProfiler: An R package for comparing biological themes among gene clusters

Diagnosis and counseling of fetal and neonatal HCMV infection

Herpes simplex virus 1 E3 ubiquitin ligase ICP0 protein inhibits tumor necrosis factor alpha-induced NF-κB activation by interacting with p65/RelA and p50/NF-κB1

Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages

The authors have declared that no competing interests exist.

Na Li performed SILAC cell experiments, analyzed the data, prepared figures and tables, and drafted the manuscript. Lingfeng Zhao participated in bioinformatics analysis. Xianquan Zhan conceived the concept, guided experiments and data analysis, supervised results, wrote and critically revised the manuscript, and was responsible for the financial supports and corresponding works. All authors approved the final manuscript.

http://orcid.org/0000-0002-4984-3549

Additional Supporting Information may be found online in the supporting information tab for this article.How to cite this article: Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol.2020;1-17. https://doi.org/10.1002/jcp.30055